Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor pediatric NASH PK/PD study
2019-003400-12Phase 2
- Sponsor
- Genfit
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elafibranor in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Genfit. Primary endpoint: Plasma concentrations of elafibranor and its active metabolite GFT1007.
02
Drugs
elafibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2019-003400-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003400-12.